CD38 and plasma cell myeloma: Based on the actual inability to reach a “cure” in MM, ongoing clinical studies are evaluating BsAbs in combination with other agents as IMiDs and PIs anti-CD38 mAbs, from which we could expect a further increase in their anti-myeloma activity, with the interesting question of novel toxicities to fight.